Business Context and Reporting Period
Company: NanoViricides, Inc. (NNVC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Stage: Development Stage Company
Operations: The Company is a nano-biopharmaceutical firm focused on discovering and developing therapeutics for viral infections (HIV, Hepatitis, Rabies, Influenza, Ebola, Dengue, etc.). It holds an exclusive perpetual license from TheraCour Pharma, Inc. for its core technology. The Company has no commercial products, no customers, and no revenues to date.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2008 | Cumulative (Inception to Sep 30, 2008) |
|---|---|---|
| Revenues | $0 | $0 |
| Net Loss | $(744,757) | $(9,952,494) |
| Operating Expenses | $756,834 | $9,293,640 |
| Cash and Cash Equivalents (Ending) | $2,985,247 | N/A |
| Net Cash Used in Operating Activities | $(640,493) | $(7,347,458) |
| Net Cash Provided by Financing Activities | $3,227,554 | $10,980,399 |
| Total Assets | $4,151,874 | N/A |
| Total Liabilities | $1,001,638 | N/A |
| Shareholders' Equity | $3,150,236 | N/A |
Debt: The Company currently has no long-term debt. Current liabilities include accounts payable to trade ($269,133) and related parties ($546,749), as well as accrued payroll to officers ($92,756).
Material Changes vs. Prior Period
- Liquidity Improvement: Cash and cash equivalents increased significantly from $816,386 at June 30, 2008, to $2,985,247 at September 30, 2008. This was driven primarily by a private placement of common stock and warrants in August 2008, raising approximately $3.23 million in net proceeds.
- Increased Operating Loss: Net loss for the quarter increased to $(744,757) compared to $(574,732) in the same period of 2007. This was due to higher Research and Development expenses ($230,750 vs. $158,814) and General and Administrative expenses ($526,084 vs. $423,832).
- Asset Growth: Total assets more than doubled from $1.47 million to $4.15 million, largely due to the cash infusion and increased property and equipment ($562,436 vs. $133,738).
- Equity Issuance: The Company issued 3,286,000 shares of common stock and warrants to purchase 1,643,000 shares in August 2008. Additionally, shares were issued for services rendered and legal fees.
Outlook, Risks, and Management Commentary
Going Concern: The filing explicitly states that the Company's significant operating losses and capital requirements raise substantial doubt about its ability to continue as a going concern. Management plans to raise funds through public and private offerings to sustain operations.
Capital Requirements: Management estimates a need for an additional $3,000,000 to $5,000,000 over the next 12 months to fund operations, capital costs, and staffing. Current cash reserves are projected to support operations only through June 30, 2009, at current spending rates.
Development Pipeline: The Company is advancing several pre-clinical drug candidates, including RabiCide (Rabies), FluCide (Influenza), HIVCide (HIV), and EKCCide (Eye disease). All programs are in the pre-clinical stage. The Company aims to file Investigational New Drug (IND) applications with the FDA in the future.
Key Risks:
- Financing Risk: Failure to secure additional financing could force the Company to curtail or cease operations.
- Licensing Risk: Operations are heavily dependent on the license agreement with TheraCour Pharma, Inc. Termination or failure to amend this agreement could halt development.
- Internal Controls: Management disclosed material weaknesses in internal controls over financial reporting, specifically regarding the timeliness of reporting and segregation of duties following the departure of the CFO in 2007.
- Development Risk: No assurance exists that drug candidates will prove effective in human trials or achieve regulatory approval.
Investor Verification Checklist
- Cash Runway: Verify if the Company has secured the projected $3M-$5M in additional financing required to operate beyond June 2009.
- Licensing Status: Confirm the status of the license agreement with TheraCour Pharma, Inc., specifically regarding the inclusion of Dengue and other viruses and the payment of development fees.
- Internal Controls: Monitor progress on remediation of material weaknesses in financial reporting and the appointment of a permanent CFO.
- Dilution: Assess the impact of recent and potential future equity issuances on existing shareholders, given the high volume of warrants and options outstanding.
- Regulatory Milestones: Track progress on pre-clinical studies and the timeline for filing IND applications for key candidates like HIVCide and RabiCide.